Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ferucarbotran + human islets
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Nanoparticles → Drug Delivery Systems, Cell Therapies, Small Molecules
- Administration
- Intraportal
01
Overview
ferucarbotran + human islets is a specialized cell therapy product consisting of donor-derived human pancreatic islets of Langerhans that have been ex vivo labeled with the superparamagnetic iron oxide (SPIO) nanoparticle ferucarbotran. This combination is primarily developed to facilitate the non-invasive tracking and longitudinal monitoring of islet grafts following transplantation into patients with Type 1 Diabetes Mellitus. The human islets provide the biological function of insulin secretion to restore glycemic control, while the ferucarbotran serves as an MRI contrast agent. By creating local magnetic field inhomogeneities, ferucarbotran significantly reduces T2 and T2* relaxation times, appearing as distinct hypointense areas (signal voids) on Magnetic Resonance Imaging. This allows clinicians to monitor the localization, distribution, and potential rejection or loss of the transplanted islet mass, addressing a major challenge in cell-based regenerative medicine.
- Other names
- ferucarbotran-labeled human isletsSPIO-labeled human isletsResovist-labeled human isletssuperparamagnetic iron oxide-labeled human islets
Beyond the preview
Go deeper on ferucarbotran + human islets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ferucarbotran + human islets.